Longitudinal association between overweight years, polygenic risk and NAFLD, significant fibrosis and cirrhosis
Alimentary Pharmacology & Therapeutics · 2023
DOI: 10.1111/apt.17452 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2023. Written by Veeral Ajmera and 4 co-authors. Institution: NAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, California, USA. Major MEDLINE topics: Non-alcoholic Fatty Liver Disease, Elasticity Imaging Techniques. Cited 17 times so far (Crossref); 25 references. The full text is freely available in PubMed Central. Funded by: NIDDK NIH HHS, NHLBI NIH HHS, NCATS NIH HHS.
Abstract (original language)
Background
Adiposity amplifies the genetic risk of non‐alcoholic fatty liver disease (NAFLD).
Aim
We evaluated the association between overweight‐years, a cumulative exposure based on the product of the duration and severity of excess body weight (body mass index (BMI) ≥ 25 kg/m 2 ), and genetic risk on liver fat and fibrosis.
Methods
This is a longitudinal analysis derived from a prospective cohort of adults in the Framingham Heart Study who underwent genotyping and vibration‐controlled‐transient‐elastography with controlled attenuation parameter. Univariable and multivariable linear and logistic regression analyses were used to assess the association between overweight‐years and liver fat and fibrosis. The association between genetic variants of liver fat ( PNPLA3 , TM6SF2 , GCKR ) and fibrosis ( PNPLA3 , TM6SF2 , HSD17B13 ) was also assessed using a polygenic risk score.
Results
Our sample included 2478 participants (54% women) with mean age and BMI of 40 (±8.5) years and 26.5(±5.1) kg/m 2 , respectively. The mean follow‐up was 14(±0.9) years, and each participant underwent three study visits. The prevalence of NAFLD was 28.3% ( n = 700), and 207 (8.4%) had clinically significant fibrosis. In age‐, sex‐ and diabetes‐adjusted multivariable analyses, overweight‐years (per SD) had a strong association with NAFLD (aOR 3.53 [95% CI: 3.10–4.02], p < 0.001), clinically significant fibrosis (aOR 1.60 [95% CI: 1.40–1.84], p < 0.001) and cirrhosis (aOR 1.81 [95% CI: 1.38–2.37], p < 0.001). High‐polygenic risk was significantly associated with liver fat and clinically significant fibrosis ( p < 0.05).
Conclusion
Overweight‐years is strongly associated with NAFLD and clinically significant fibrosis and combined with polygenic risk may assist in defining the trajectory of NAFLD.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- NAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, California, USA.
- Division of Gastroenterology, University of California at San Diego, La Jolla, California, USA.
- Biostatistics and Epidemiology Data Analytics Center, Boston University School of Public Health, Boston, Massachusetts, USA.
- Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA.
- Section of Gastroenterology, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts, USA.
ORCID profiles: Veeral Ajmera
Funding
- NIDDK NIH HHS
- NHLBI NIH HHS
- NCATS NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- Doris Duke Charitable Foundation
Cite
APA
Ajmera, V., Wang, N., Xu, H., Liu, C. T., & Long, M. T. (2023). Longitudinal association between overweight years, polygenic risk and NAFLD, significant fibrosis and cirrhosis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17452
Vancouver
Ajmera V, Wang N, Xu H, Liu CT, Long MT. Longitudinal association between overweight years, polygenic risk and NAFLD, significant fibrosis and cirrhosis. Alimentary Pharmacology & Therapeutics. 2023. doi:10.1111/apt.17452
BibTeX
@article{Ajmera2023,
author = {Ajmera, Veeral and Wang, Na and Xu, Hanfei and Liu, Ching-Ti and Long, Michelle T},
title = {Longitudinal association between overweight years, polygenic risk and NAFLD, significant fibrosis and cirrhosis},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2023},
doi = {10.1111/apt.17452}
}
EUVIMED